Free Trial
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

$3.83
+0.13 (+3.51%)
(As of 07/17/2024 ET)
Today's Range
$3.76
$3.85
50-Day Range
$1.45
$3.74
52-Week Range
$1.08
$5.50
Volume
18,461 shs
Average Volume
18,829 shs
Market Capitalization
$30.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKTX stock logo

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

AKTX Stock News Headlines

Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update
Get our #1 stock for this rare market event now
Former hedge fund manager: "Move your money before the Fed's next meeting on July 31" In 2022, the Federal Reserve raised interest rates and triggered a stock market event that slashed the average investor's portfolio nearly in half. Now, according to the man whom CNBC calls 'The Prophet', the Fed could soon trigger another dramatic stock event – one investors have seen just 13 times since 1920. He warns: "This event will likely dictate the next decade of every American's financial life, and it's critical for you to take steps now to prepare."
Get our #1 stock for this rare market event now
Former hedge fund manager: "Move your money before the Fed's next meeting on July 31" In 2022, the Federal Reserve raised interest rates and triggered a stock market event that slashed the average investor's portfolio nearly in half. Now, according to the man whom CNBC calls 'The Prophet', the Fed could soon trigger another dramatic stock event – one investors have seen just 13 times since 1920. He warns: "This event will likely dictate the next decade of every American's financial life, and it's critical for you to take steps now to prepare."
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2020
Today
7/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKTX
Employees
9
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.03) per share

Miscellaneous

Free Float
4,842,000
Market Cap
$30.33 million
Optionable
Not Optionable
Beta
0.91
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Key Executives

  • Ms. Rachelle Suzanne Jacques (Age 53)
    President, CEO & Director
    Comp: $632.25k
  • Ms. Wendy F. DiCicco CPA (Age 57)
    Interim Chief Financial Officer
    Comp: $540.34k
  • Ms. Melissa Bradford-Klug (Age 54)
    Chief Operating Officer
  • Dr. Miles Nunn (Age 55)
    Chief Scientific Officer
  • Dr. John F. Neylan III (Age 71)
    M.D., Executive VP & Chief Medical Officer

AKTX Stock Analysis - Frequently Asked Questions

How have AKTX shares performed this year?

Akari Therapeutics' stock was trading at $3.12 at the beginning of 2024. Since then, AKTX shares have increased by 22.8% and is now trading at $3.83.
View the best growth stocks for 2024 here
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) announced its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share for the quarter, missing the consensus estimate of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Akari Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL) and Rigel Pharmaceuticals (RIGL).

This page (NASDAQ:AKTX) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners